Allergan has confirmed Prednefrin Forte (prednisolone acetate and phenylephrine hydrochloride) eye drops (10mL) will be available once again across Australian pharmacies in February 2022. Read more
Glaukos has commenced Phase 2 trials of two investigational cream-based drug candidates that are applied to the eyelids to treat dry eye and presbyopia. Read more
Novartis has announced it is acquiring Gyroscope Therapeutics, the UK-based company behind an investigational dry ADM gene therapy that is the focus of key clinical trials in Australia. Read more
The vitreoretinal surgeon who performed Australia’s first Luxturna gene therapy has described the intricacy of the procedure, while hailing the team effort that has resulted in profound vision improvements for patients, including one who reported seeing stars for the first time.
Ivantis has revealed new data from its five-year HORIZON pivotal trial showing its Hydrus Microstent device lowers the rate of visual field loss by 47% versus cataract surgery alone. Read more
Australian optometrists will be able to prescribe dry eye therapy lifitegrast (Xiidra) from next month without the involvement of a medical practitioner, under updated Optometry Board of Australia (OBA) rules. Read more
In 2016, at his home RANZCO scientific branch meeting in Tasmania, preeminent ophthalmic genetics expert Professor Alex Hewitt presented on the transformative impact of CRISPR/Cas9 gene editing for inherited retinal diseases (IRDs).
New seven-year findings from CooperVision’s MiSight 1 day contact lens clinical trial shows no evidence of myopia control rebound in children 12 months after treatment has ended. Read more
US regulators have approved the country’s first presbyopia eye drop that adopts pupil constriction to improve near and intermediate vision while maintaining some pupillary response to different lighting conditions. Read more
The US Food and Drug Administration (FDA) has approved the Susvimo implant which delivers ranibizumab continuously, offering patients living with neovascular age-related macular degeneration (nAMD) an alternative to more frequent anti-VEGF eye injections. Read more